Figure 1.
Summary of reviewed biomarkers of response to immune checkpoint inhibitor (ICI) therapies for melanoma patients. PD-L1: programmed death ligand 1, MHC I: major histocompatibility complex class I, MHC II: major histocompatibility complex class II, ctDNA: circulating tumor DNA, MDSC: myeloid-derived suppressor cells, Tregs: regulatory T-cells, TIL: tumor infiltrating lymphocytes.